Clinical Trials

Other hematologic neoplasm

86 enrolled

Leukemia, Hairy Cell

NCT07003295 2026-03-18

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Lymphoma, Mantle-Cell

NCT07218510 2026-03-13

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

33 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04169737 2026-02-24

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05536349 2026-02-24

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Other hematologic neoplasm

60 enrolled

Leukemia

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06558604 2026-02-11

GLOASIS

100 enrolled

Lymphoma, Mantle-Cell

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04895436 2026-02-09

ReVenG

75 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-02-04

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06333262 2026-01-21

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Lymphoma, B-Cell

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

70 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04505254 2025-12-26

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06108232 2025-12-19

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

36 enrolled

Lymphoma, Follicular, Neoplasms

NCT06765317 2025-11-26

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06967610 2025-11-06

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06252675 2025-10-22

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

30 enrolled

Lymphoma, Mantle-Cell

NCT06849713 2025-09-25

BOSon

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03824483 2025-09-23

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02393157 2025-08-08

O-ICE

25 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06959732 2025-05-07

Zanubrutinib Combined With G-CVP in Previously Untreated FL

Lymphoma, Follicular

NCT04450173 2025-04-24

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Lymphoma, Follicular

NCT06544785 2024-10-24

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

106 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06566807 2024-08-22

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

51 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT06504199 2024-08-09

ZGR

39 enrolled

Lymphoma, Mantle-Cell

NCT06513234 2024-07-22

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

45 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT06454968 2024-06-18

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

45 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT05833763 2024-01-08

GOlDiLOX

42 enrolled

Lymphoma, Mantle-Cell

NCT05848765 2023-11-29

REFRACT

284 enrolled

Lymphoma, Lymphoma, Follicular

NCT04908228 2023-10-03

FIGHT

53 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05846750 2023-07-19

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

59 enrolled